| Característica |
Objectiu de la convocatòria
In 2026, this grant program will support projects aimed at understanding, preventing, and overcoming resistance to lung cancer therapies. Funded work may address mechanistic questions and developmental therapeutics across all lung cancer subtypes— including adenocarcinoma, squamous cell carcinoma, and small cell lung cancer— and throughout the care continuum, including new targeted therapies and immunotherapies.
|
Característiques principals
Project topics include, but are not limited to:
Mechanisms of resistance to targeted therapies for oncogene-driven lung cancers. Proposals are encouraged in the areas of histological transformation, oligometastatic disease, oligo-remnant disease, uncommon mutations and non-genomic mechanisms of resistance.
Biology and mechanisms of drug resistance to lung cancer therapies including chemotherapy, immunotherapy, radiotherapy, and antibody drug conjugates.
Novel treatment approaches and new therapies to overcome and/or prevent resistance to lung cancer therapies.
Novel diagnostic approaches (i.e. biomarkers) to monitor treatment response and relapse.
Overcoming resistance in difficult to treat sites of metastases such as leptomeningeal and brain metastases.
|
Lloc de presentació
HMRIB and PSMAR staff who need more information should contact:
Research Grants and Contracts Office. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00.
Carol Barnwell: [email protected] Ext.: 1670
Marta López: [email protected] Ext.: 1576
Júlia Vidal: [email protected] Ext.: 1736
|
Convocatòria (URL)
https://www.lungcancerresearchfoundation.org/research/funding-opportunities-2026/
|
Informació addicional
All applications for funding must be submitted online at Proposal Central through a two-stage process consisting of a letter of intent (LOI) and full proposal.
|
Requisits
Investigators must be primarily affiliated with a non-profit academic or research institution and must be post-doctoral researchers, clinical fellows, or early-career and mid-career investigators with less than seven years' experience since their initial faculty appointment. Exceptions may be granted for investigators with more years of experience in other disease areas or research topics.
Applicants from US-based and international institutions are eligible to apply and may hold any residency/citizenship status.
Applicants who have received or are receiving LCRF funding in the last four years are not eligible to apply.
Applicants may submit only one LCRF grant application per award cycle either as lead investigator or co-investigator.
Senior investigators with more than seven years' experience since faculty appointment are generally not eligible for funding and are encouraged to mentor a junior team member through the application process.
|
Dotació
USD 75,000 per year
|
Durada
Two years
|